The conversation about menopause tends to collapse quickly into “try HRT” - and when someone has a bad reaction to the patch, there’s often no clear next step offered. That gap is real, and it’s partly because a genuinely new category of treatment only landed a couple of years ago and hasn’t made it into most GP consultations yet. Fezolinetant (Veozah in the US) got FDA approval in May 2023 specifically for vasomotor symptoms - hot flashes, night sweats. It’s a neurokinin-3 receptor antagonist, which sounds technical, but the practical point is that it works on the hypothalamic pathway driving the temperature dysregulation rather than on estrogen receptors at all. Different mechanism entirely, different risk profile from HRT. From the compounding side - I work at a 503A pharmacy - interest in this class picked up noticeably after that approval. The licensed version is expensive and coverage is inconsistent, which is part of why it hasn’t filtered through to most GPs yet. But it exists as a real licensed option, and it’s worth raising explicitly w/ a consultant if systemic estrogen is off the table for you. One thing worth knowing if you’ve had a partial hysterectomy and have no uterus: you don’t need progestogen. Not all GPs communicate that clearly upfront. It simplifies the conversation considerably when you’re discussing non-estrogen alternatives. Tracking response to a new treatment really does matter here - night sweat frequency, severity, what time of night, across a few weeks. I use CareClinic for dose-day reminders and check-ins so the log doesn’t go patchy between appointments. Consistent data is what lets you actually compare a new treatment against your baseline.
The hepatotoxicity signal is the piece that tends to get dropped from “different mechanism, different risk profile” framing - which is true as far as it goes, but incomplete. Veozah’s label includes baseline and periodic liver enzyme monitoring requirements because elevated transaminases showed up at higher frequency in the trials. imo not disqualifying, and it’s not a reason to avoid the drug, but it’s a variable worth naming before someone hears “different risk profile from HRT” and concludes it’s a clean swap with no flags. the risk profile is genuinely different - it’s just not the same as risk-free, and that distinction is doing some work in how this class gets discussed
Grade 1-2 elevations were the bulk of what appeared in the trial data, so the transaminase signal is real but the clinical weight is different from actual hepatic events - worth being specific when someone’s weighing this against a genuine treatment gap. agreeing the framing gets sloppy when it collapses into “different mechanism, therefore different risk profile, full stop.” the point about “risk profile is genuinely different” not meaning “risk-free” is exactly the distinction that needs to stay in the conversation.
fwiw the caveat i’d add: naming the monitoring requirement in an abstract discussion of the drug isn’t the same as the monitoring actually happening. a lot of access to fezolinetant right now runs through telehealth with thin follow-up structures, and “baseline and periodic liver enzyme monitoring” on the label can functionally translate to nobody ordering a CMP before or after the first fill. the label flag is real and it’s there for a reason. whether it’s getting actioned in the actual access channels where this drug is reaching people - coverage gaps, inconsistent GP awareness, telehealth workarounds - is a legitimately separate question, and imo one worth naming when the conversation is about real-world risk rather than trial-design risk.
“The monitoring not getting actioned” is the strongest point here, but pinning it to fezolinetant’s access channel specifically undersells how generalizable the problem is. Compounded sema via the same telehealth stack rarely comes with baseline cardiometabolic labs. Gabapentin and paroxetine scripts for vasomotor symptoms aren’t getting baseline LFTs either. It’s a telehealth prescribing problem, not an NK3 antagonist problem - and framing it that way matters if the implicit takeaway is extra skepticism toward fezolinetant over its alternatives.